Corrects FY Cash & Investments figure in Key Details table to EUR 2.998 bln from -EUR 44.80 mln
Overview
Belgium-based biotech's 2025 net revenue rose 304% yr/yr, driven by Gilead collaboration
Company reported 2025 net profit of €320.9 mln, up from €74.1 mln in 2024
Company expects to be cash flow neutral to positive by end of 2026
Outlook
Galapagos expects 2026 year-end cash between €2.775 bln and €2.850 bln
Company anticipates cash flow neutral to positive by end of 2026
Result Drivers
GILEAD COLLABORATION - Revenue growth driven by full recognition of deferred income from Gilead collaboration
CELL THERAPY WIND-DOWN - Strategic wind-down of cell therapy activities resulted in impairment costs
Company press release: ID:nGNE4k1xC7
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | EUR 1.11 bln | ||
FY Net Income | EUR 320.90 mln | ||
FY Cash & Investments | EUR 2.998 bln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Galapagos NV is €28.95, about 1.9% above its February 23 closing price of €28.40
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)